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Given that several targeted therapies directed towards folate receptor alpha (FRA) are in late stage clinical
development, the sensitive and robust detection of FRA in tissues is of paramount importance relative to patient
selection, prognosis and prediction. In the present study we undertook an immunohistochemical evaluation of
expression of FRA in breast cancer samples using formalin-fixed, paraffin-embedded (FFPE) tissues, primarily invasive
ductal carcinomas, using a newly described monoclonal antibody, 26B3. Samples assessed included both tissue
microarrays (TMA) and whole tissue sections from archival tissue blocks. Normal breast shows a highly restricted
expression of FRA to luminal membrane staining of secretory ductal cells, consistent with FRA secretion into milk. In
early stage (stages I-III) invasive ductal carcinomas, FRA staining was observed in approximately 30% of all samples,
independent of molecular subtype (estrogen receptor (ER)/progesterone receptor (PR)/human epidermal growth
factor receptor type 2 (Her2)). However, FRA expression was shown to associate with ER/PR negative tumors relative
to ER/PR positive tumors (p = 0.012) and perhaps more importantly, with triple negative breast cancers (TNBC;
p < 0.0001). FRA immunoreactivity was also shown to be retained in stage IV metastatic breast cancer samples from
diverse anatomic sites including lymph node and bone. In metastatic breast cancer, FRA was shown to be
expressed in 86% of TNBC patients. Taken together, these data suggest that FRA expressing breast cancer
represents a novel molecular subtype and, further, may represent a new therapeutic target for this devastating
disease.
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According to Global Cancer Facts & Figures 2nd Edition,
in 2008 the estimated worldwide new cases for breast can-
cer were 1,383,500 with a projected 458,400 deaths and a
mortality rate of approximately 33%. In the U.S., 229,060
new cases of breast cancer and 39,920 deaths from this
disease are expected in 2012 (Siegel & Naishadham 2012).
Treatment for breast cancer is currently tailored according
to cellular protein expression. Estrogen receptor/proges-
terone receptor (ER/PR) expressing breast cancers are
treated with endocrine therapy. The treatment armament-
arium of human epidermal growth factor receptor 2
(Her2) overexpressing breast cancers includes an anti-* Correspondence: doshannessy@morphotek.com
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reproduction in any medium, provided the origHer2 agent. The triple negative breast cancers (TNBC)
that do not express ER, PR or Her2 are treated with trad-
itional cytotoxic chemotherapy alone. New therapeutic
approaches for this poor prognosis breast cancer subtype
are sorely needed.
Folate, or vitamin B9, is an essential cofactor in the syn-
thesis of purines and pyrimidines and other cellular
methylation reactions including DNA, proteins and lipids
(Elnakat & Ratnam 2004). The folate receptors (folate re-
ceptor alpha, FRA; beta, FRB, gamma, FRG; and delta,
FRD) constitute a family of proteins that, at least in part,
mediate accumulation of folate into cells, regulate folate
homeostasis and may have effects on cellular proliferation
(Elnakat & Ratnam 2004; Kelemen 2006). FRA, a glycosyl-
phosphatidylinositol (GPI)-anchored cell surface glycopro-
tein, has a very limited tissue distribution. In normal
tissue, FRA is mainly expressed on the apical surface of ais is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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ney, lung, thyroid and breast (Weitman et al. 1992a; Weit-
man et al. 1992b; O’Shannessy et al. 2011; O’Shannessy
et al. 2012). Previous studies have also reported FRA to be
expressed on carcinomas of the ovary and endometrium,
non-small cell lung adenocarcinoma, clear cell renal car-
cinoma, colorectal carcinoma, and breast carcinoma
(Weitman et al. 1992a; Weitman et al. 1992b; O’Shannessy
et al. 2011; O’Shannessy et al. 2012; Franklin et al. 1994;
Ross et al. 1994; Wu et al. 1999; Bueno et al. 2001; Parker
et al. 2005; Shia et al. 2008).
The limited tissue distribution of FRA and its specific
expression on certain malignancies makes FRA an at-
tractive target for directed therapies. Indeed, the poten-
tial to exploit the differential expression of FRA for
targeted cancer therapy has long been appreciated. Two
primary approaches have been explored, one involving
targeted drug delivery via folate-conjugated therapeutic
compounds that binds both FRA and FRB (Low &
Kularatne 2009; Dosio et al. 2010), while another ap-
proach involves direct targeting and tumor cell death via
humanized anti-FRA monoclonal antibodies (Ebel et al.
2007; Konner et al. 2010; Spannuth et al. 2010). Both
approaches have advanced to late-stage clinical develop-
ment in ovarian cancer.
In order to further support the development of such
therapeutic strategies, it is important to identify patients
who may benefit from FRA-targeted therapy, particularly
in cancers where the frequency and degree of expression
is not ubiquitous, such as in breast cancer (Franklin
et al. 1994; Shia et al. 2008; Stein et al. 1991). Addition-
ally, reports that FRA expression levels may be asso-
ciated with disease stage or survival in ovarian cancer or
non-small cell lung cancer, suggest that FRA may be a
useful prognostic marker (O’Shannessy et al. 2012; Tof-
foli et al. 1997; Toffoli et al. 1998; Iwakiri et al. 2008).
Specific and sensitive methods to detect FRA expression
in biological samples such as tissue are essential if it is
to be pursued as a potential anti-cancer therapy.
Here we describe and define the expression pattern of
FRA in breast cancer using a recently reported monoclo-
nal antibody, MAb 26B3 (O’Shannessy et al. 2011;
O’Shannessy et al. 2012), and demonstrate a strong asso-
ciation of FRA expression with TNBC. FRA expressing
breast cancers may represent a unique and novel mo-
lecular subtype of breast cancer that may be amenable
to FRA-targeted therapeutic interventions.
Materials and methods
Tissues
Commercial tissue microarray (TMA)
The breast cancer TMA [breast invasive ductal carcin-
omas (catalog # BR1503a; 72 cases, duplicate cores)] was
obtained from US Biomax, Inc. (Rockville, MD).Demographic details for this TMA can be found at: http://
www.biomax.us/. These samples were predominantly from
women under the age of 60 (range = 19-69 years).Whole section FFPE slides
Individual formalin-fixed, paraffin-embedded (FFPE) slides
were obtained from the archives of Genzyme Genetics.
No information is available on the treatment regimens
for the patients that contributed the samples analyzed in
the present study.Immunohistochemistry
IHC was performed using FFPE specimens (TMA or
whole sections) and a MACH4 Universal HRP-Polymer
Detection Kit (Biocare Medical, Concord, CA). FFPE
specimens were sectioned at 5 um onto positively-
charged glass slides and heated for approximately
60 min at 60°C. Slides were deparaffinized in three se-
quential baths of xylene for 3 min each, transferred to
three sequential baths of 100% alcohol for 3 min each,
followed by three sequential baths of 95% alcohol for
3 min each and then rinsed for 5 min in deionized (DI)
water. Slides were then pretreated in Diva heat-induced
epitope retrieval solution (Biocare Medical) diluted 1:10
in DI water and placed inside a pressurized decloaking
chamber already filled with 500 mL of DI water. For
antigen retrieval, slides were incubated for 15 min inside
the decloaking chamber in which pressurized incubation
reaches a maximum of 125°C at 16 PSI for 30 sec and
then cooled for 15 min down to 95°C. After cooling to
RT, slides were washed in three sequential baths of Tris
Buffered Saline/0.1% Tween-20 wash buffer (TBST) for
3 min each and subsequently placed into Peroxidase-1
(Biocare Medical) blocking solution for 5 min at RT.
After washing in TBST as above, Background Sniper
(Biocare Medical) serum-free universal blocking reagent
was applied for 10 min at RT. Slides were then incu-
bated with purified MAb 26B3.F2 (O’Shannessy et al.
2011) at 2.5 μg/mL diluted in Antibody Diluent (Dako
North America, Inc., Carpinteria, CA) or Universal
Negative Control [mouse ready-to-use negative control
antibody (Dako, for negative isotype tissue)] for 60 min
at RT. After washing, slides were incubated with
MACH4 Mouse Probe Primary Antibody Enhancer for
15 min, followed by Polymer-HRP reagent for 20 min,
developed with a 3,3'-diaminobenzidine tetrahydrochlor-
ide (DAB) solution (Dako) for 5 min and counterstained
with hematoxylin (Dako) for 2 min, all incubations being
performed at RT. Scoring for staining was performed by
a single board-certified pathologist, using customary
scoring for intensity and the percent of the tumor
stained at each intensity.
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In this study, FRA IHC membrane and intracellular
staining intensity was scored as 0, no staining; 1+, weak;
2+, moderate and 3+, strong. The percent of cells stain-
ing at each intensity in the sample was also determined.
Sections were analyzed under 4x, 10x, 20x and 40x
objectives. 3+ strong membrane staining was readily
visualized under 4x and confirmed at 10x objective. 2+
moderate membrane staining was visible at 10x and
confirmed at 20x, whereas 1+ weak staining required
20x or 40x objectives (Figure 1 a-d). In the presence
of 3+ staining, the membrane was thick and occurred at
apical and lateral cell borders. In tangential sections, a
complete circumferential pattern was evident (Figure 1a).
2+ membrane staining was weaker in intensity and thin-
ner than 3+ membrane staining, usually localized on
the apical luminal borders and occasionally on lateral
cell borders. 1+ weak membrane staining was generally
limited to the luminal borders. The accompanying
intracellular staining was variable, depending on the
type of tumors.ba
dc
Figure 1 FRA IHC scoring criteria. a Strong 3+ membrane staining
is clearly visible at 10x. The membrane staining is intense, thick and
circumferential (x10). b 2+ moderate membrane staining on the
luminal borders of malignant cells in a poorly differentiated ductal
carcinoma (x20). c 1+ weak membrane staining is seen on the
luminal border of poorly differentiated ductal carcinoma cells. It
requires 40x objective to visualize the thin, incomplete membrane
staining (x40). d No membrane staining is seen in this well-
differentiated ductal carcinoma (x20).Statistical analyses
All statistical analyses were performed using GraphPad
Prizm 5 (GraphPad Software Inc., La Jolla, CA).
Positive staining result and TMA core rejection
A sample (TMA core or FFPE slide) was considered
positive for FRA expression if the percentage of the
tumor area considered by the reading pathologist (Y-S
Fu) to be positive for membranous staining was greater
than or equal to 5% at any intensity. A TMA core was
rejected and therefore not included in the analyses if the
reading pathologist determined it was either missing en-
tirely (empty core), was composed of necrotic tissue or
was deemed to represent normal tissue. Histopathologic
diagnosis of cores was made by the reading pathologist.
The M-Score – a semi-quantitative staining algorithm
The M-score (O’Shannessy et al. 2012), a metric for









In the equation, xij is the percentage of tumor stained
at intensity j for patient i and wj is the absolute value of
the intensity. The metric has a theoretical range from
zero (no positive staining) to 50 (100% 3+). As such, the
M-score is a weighted score of FRA IHC tumor cell
membrane staining that captures both the proportion of
FRA positive cells and staining intensity.
The M-scores for each patient/sample were averaged
over duplicate TMA cores, where appropriate. If a deter-
mination (core) was void of results, i.e. no tumor present
or necrotic tissue, the M-score was assigned to the non-
void determinations.
The expression rate for FRA expression was calculated
as the proportion of tumors that were stained positive
according to the definition of a positive result (≥5%
tumor cell membrane staining). This procedure was also
applied within specific histology subgroups. Differences
for mean values were determined using Fisher’s exact
test or one-way ANOVA with post hoc tests controlling
for overall type I error.
Results
As previously described (O’Shannessy et al. 2011), MAb
26B3 is a unique, high affinity antibody shown to be
highly specific for FRA with no cross-reactivity to the
other three members of this receptor family, namely
FRB (folate receptor beta), FRG (folate receptor gamma)
or FRD (folate receptor delta). MAb 26B3 has been
shown to recognize FRA on FFPE sections of various
normal tissues, including breast (O’Shannessy et al.
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26B3 was consistent with a membranous localization
(Figure 1), although diffuse intracellular staining was
also observed. In the absence of membrane staining,
intracellular staining was rarely present. Intracellular
staining for FRA is expected given that the receptor
cycles, carrying folates with it, to the intracellular com-
partment while remaining membrane associated, by an
endocytotic mechanism (Elnakat et al. 2009).b
Figure 2 FRA staining in normal breast tissue and DCIS.
a Normal breast tissue: strong 3+ membrane staining is seen on the
luminal border of secretory cells. Myoepithelial cells in the outer
layer of the duct are not stained (x40). b Ductal carcinoma in situ of
breast, intermediate grade: the majority of tumor cells reveal 3+
strong or 2+ moderate membrane staining on the luminal and
lateral cell borders (x20).FRA expression on the breast cancer TMA
The distribution of histologies present on the breast can-
cer TMA are shown in Table 1, the majority (83%) of the
cases represented being identified as invasive ductal car-
cinoma (IDC). The TMA included two normal breast
samples, and as previously described (O’Shannessy et al.
2011; O’Shannessy et al. 2012), both were positive for FRA
expression as determined by MAb 26B3. Membrane stain-
ing of normal breast is restricted to the luminal borders of
secretory cells while myoepithelial cells in the outer layer
of the duct are negative (Figure 2a). The staining of nor-
mal breast is not unexpected in that FRA is secreted into
breast milk and believed to be a source of bound folates
for the developing embryo (Elnakat & Ratnam 2004).
Of the 71 evaluable cases on the TMA, 21 (30%) were
shown to be FRA(+) using the criteria of ≥5% of tumor
cells exhibiting membrane staining. Two of three fibro-
adenoma cases (67%), 0/2 cystosarcoma cases (0%) and
1/6 ductal carcinoma in situ (DCIS) cases (17%) were
FRA(+) (Figure 2b). The single invasive lobular carcin-
oma (ILC) was FRA(−). The small number of samples
represented by these histologies precludes any definitive
statement with respect to FRA expression rates and fur-
ther work is warranted. However, of the 59 IDC samples
18 (31%) were FRA(+) (Table 2). In this sample set, no
significant differences were noted for FRA expression in
IDC relative to stage, nodal status or grade (Table 2),Table 1 Distribution of FRA expression across breast
histologies – TMA data
Histology FRA positive FRA negative Total
N (%) N (%)
Normal 2 (100%) 0 (0%) 2
Fibroadenoma 2 (67%) 1 (33%) 3
Cystosarcoma 0 (0%) 2 (100%) 2
DCIS – Ductal carcinoma in situ 1 (17%) 5 (83%) 6
ILC – Invasive lobular carcinoma 0 (0%) 1 (100%) 1
IDC – Invasive ductal carcinoma 18 (31%) 41 (69%) 59
Total samples: 21 (30%) 50 (70%) 71
FRA folate receptor alpha, TMA tissue microarray.although it should be noted that the number of FRA(+)
samples in this analysis is relatively small.
Of the 18 FRA(+) IDC cases, the majority (89%) were
Her2(−) suggesting that FRA expression is negatively
correlated with Her2 expression in breast cancer
(Table 2). Further, of the 18 FRA(+) IDC cases there was
a statistically significant difference between ER/PR(+)
and ER/PR(−) cases (p = 0.012; Table 2). In addition, of
the 4 FRA(+) samples that were also ER/PR(+), all were
Her2(−). A statistically significant difference was seen
for FRA(+) samples relative to expression of either ER,
PR or Her2 versus ER/PR/Her2(−), or triple negative dis-
ease (p < 0.0001). Sixty-seven percent of the 18 TNBC
specimens express FRA (Figure 3). Taken together, these
data support the claim that FRA expression is enriched
in the TNBC subtype and may represent a novel mo-
lecular subtype of breast cancer.
Table 2 IDC molecular subtype analysis relative to FRA staining – TMA data
Variable FRA positive FRA negative Total P valuea
N (%) N (%)
Marker
ER/PR(+) 4 (14%) 24 (86%) 28
ER/PR(-) 14 (45%) 17 (55%) 31 0.012
Her2(+) 2 (15%) 11 (85%) 13
Her2(-) 16 (35%) 30 (65%) 46 0.307
ER/PR/Her2(-) 12 (67%) 6 (33%) 18 <0.0001
[ER/PR(+) or Her2(+) vs ER/PR/Her2(-)]
TNM Classification
T1 3 (43%) 4 (57%) 7
T2 10 (26%) 29 (74%) 39
T3 5 (63%) 3 (37%) 8
T4 0 (0%) 5 (100%) 5
Nodal Status
N0 18 (35%) 33 (65%) 51
N1/N2b 0 (0%) 8 (100%) 8 0.092
Tumor Grade
Grade 1 1 (14%) 6 (86%) 7
Grade 2 12 (36%) 21 (64%) 33 0.393
Grade 3 5 (26%) 14 (74%) 19 0.6465c
IDC invasive ductal carcinoma, TMA tissue microarray, FRA folate receptor alpha, ER estrogen receptor, PR progesterone receptor, Her2 human epidermal growth
factor receptor type 2, TNM tumor node metastasis.
a P values calculated via 2X2 contingency table analysis using Fisher’s exact test.
b 4/8 (50%) of N1/N2 samples were Her2(+).
c Grade 1 vs Grade 3.
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breast cancer patients
The TMA described above was composed primarily of
early stage breast cancers: stage I, 6/60 (10%); stage II,
44/60 (73%); stage III, 10/60 (17%); no metastatic breast
cancer cases were represented on the TMA (Table 3).
Therefore, to confirm and extend the results obtained
on the TMA, we identified 61 archival FFPE tissue
blocks from stage IV (T4) Her2(−) breast cancers with
known ER/PR expression ranging from 0-100% positive.
Importantly, all 61 of these samples were from metasta-
ses, not the primary tumor.
FRA expression was found in 22/61 (36%) of these
patients, demonstrating that the percent of FRA(+) speci-
mens/tumors determined in early stage disease is retained
in late stage metastatic disease, at least in a Her2(−) popu-
lation (TMA expression rate = 35%; stage IV metastatic
disease = 36%). Of the 22 FRA(+) stage IV metastatic
cases, only three (14%) showed any expression level for
ER/PR which tended to be in the low range (up to 30%).
As such, 19/22 (86%) FRA(+) patients were of the TNBC
molecular subtype. As with the data obtained in early
stage disease on the TMA, triple negative samples are
overrepresented in the FRA(+) population. However, bothdata sets support the assertion that FRA staining asso-
ciated more strongly with triple negative disease. In meta-
static disease, there was a significant difference between
FRA(+) samples that were also ER/PR(+) or ER/PR(−)
(p= 0.0054), as seen on the TMA, but also a significant
difference in FRA expression by grade of disease (grade 1
or grade 2 versus grade 3, p = 0.037).
The semi-quantitative M-score (O’Shannessy et al.
2012) was also used to analyze the pattern of FRA stain-
ing (intensity and percent of tumor cells) of metastatic
breast cancer samples. While a significant difference
could be demonstrated between the ER/PR(+) versus the
ER/PR(−) populations (Figure 4a; p = 0.0029), no such
difference was evident for grade of disease either across
the entire population (Figure 4b) or within the FRA(+)
population (Figure 4c). These data are consistent not
only with FRA expression overall, but also with the data
described for the early stage TMA samples. Taken to-
gether, the present data demonstrate a strong association
between FRA expression and TNBC and further support
the notion that FRA(+) breast cancer may represent a
new molecular subtype of this disease.
The samples represented in the FFPE blocks from
stage IV metastatic disease were obtained from a
a b
Figure 3 Triple negative [ER/PR/Her2(−)] poorly differentiated
ductal carcinoma. a Tumor cells are arranged in solid nests and
present with high nuclear grade, prominent nucleoli and active
mitosis. Cell borders are ill-defined. There are scattered apoptotic
cells with pyknotic nuclei and densely eosinophilic cytoplasm (x20).
b In the immunohistochemical stain for FRA, about 60% of tumor
cells demonstrate membrane staining ranging from 1+ to 3+ (x20).
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skin and liver, as well as fluid and fine needle aspirate
(FNA) samples obtained primarily from pleura and para-
centesis. Several of these ‘fluid biopsies’ were stained
positive for FRA (Figure 5) suggesting the general ap-
plicability of the described IHC methodology to multiple
samples types. However, given the small sample numbers
in the present study, additional work on the suitability
of FNAs as a FRA IHC diagnostic sample source are
warranted. It should be noted, however, that FNAs
have also been demonstrated to be positive for FRA
expression by IHC in non-small cell lung adenocarcin-
oma (O’Shannessy et al. 2012).Table 3 Distribution of FRA expression relative to hormone re
breast cancer cohorta
Variable FRA positive FRA neg
N (%) N (%
Marker
ER/PR(+) 3 (14%) 20 (86
ER/PR/Her2(−) 19 (50%) 19 (50
Tumor Grade
Grade 1 3 (30%) 7 (70%
Grade 2 11 (28%) 28 (72
Grade 3 8 (67%) 4 (33%
Total Samples 22 (36%) 39 (64
FRA folate receptor alpha, Her2 human epidermal growth factor receptor type 2, E
a All samples were whole tissue FFPE (formalin-fixed, paraffin-embedded) slides.
b P values calculated via 2X2 contingency table analysis using Fisher’s exact test.Discussion
Currently, breast cancer is grouped into three subtypes
that dictate therapy: ER and/or PR expressing, Her2
expressing, or TNBC which implies the absence of these
three receptors. Hormone responsive breast tumors rep-
resent approximately two-thirds of all breast cancers
(Bauer et al. 2007). Treatment at some point during the
course of therapy will necessarily include hormonal
agents. Endocrine therapy has been shown to both pro-
long life and decrease treatment related morbidity. Her2
overexpressing breast cancer represents approximately
15-20% of breast cancers (Bauer et al. 2007). Although
treatment with trastuzumab has vastly improved survival
in patients with Her2 positive tumors, the prognosis for
this group remains worse than for their hormone recep-
tor expressing counterparts. The balance of breast can-
cers lack all three of these receptors and are referred to
as triple negative.
It is unclear from the current investigation if the FRA
(+) subset represents a particular TNBC histotype. It is
conceivable that the FRA expressing cancers may fall
into the basal-like category that are also known to some-
times be BRCA(+), characterized high grade infiltrating
ductal carcinomas that can show necrosis (Metzger-
Filho et al. 2012), or by contrast the luminal androgen
receptor subtype that often present with bone and
lymph node involvement but are more indolent by na-
ture (Gelmon et al. 2012).
There are no currently available targeted therapies for
TNBC and their prognosis remains decidedly worse than
those with hormone receptor expression. Recently,
PARP inhibitors were assessed in this TNBC patient
population with the hope of improving survival and out-
come. However, a phase III randomized clinical trialceptor status and tumor grade in a Her2(−) metastatic
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Figure 4 M-score Distribution of FRA Expression in Her2(−)
Metastatic Breast Cancer. a Distribution of the level of FRA
expression in 61 Her2(−) metastatic breast cancer samples based on
molecular subtype: ER/PR(+) versus ER/PR(−) p = 0.0029 (two-tailed
t-test). b Distribution of the level of FRA expression based on grade
across 61 Her2(−) metastatic breast cancer samples. The differences
in the means of the M-scores were not significant (one-way ANOVA).
c Distribution of the level of expression of FRA across grade in FRA
positive (n = 22) metastaic breast cancer samples. The differences in
the means of the M-scores were not significant (one-way ANOVA).
b
a
Figure 5 Use of breast cancer FNAs for FRA IHC. a CTBA08494A
(40X) – A cluster of malignant cells with 3+ membranous staining
and 3+ intracellular staining. b CTBA08496A (40X) – A cluster of
malignant cells with mostly 3+ intracellular staining.
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ment for this molecular subtype of breast cancer
remains untargeted cytotoxics.
FRA is an interesting and relevant biomarker in cancer
therapy. This GPI-anchored protein at least in part
serves to bind and transport folate, primarily 5-methylte-
trahydrofolate, the predominant plasma folate, into cells.
However, its expression is not necessary for cytosolic fol-
ate accumulation and purine and pyrimidine synthesis as
there are multiple portals of folate entry, primarily the
reduced folate carrier (RFC), ubiquitous on all mamma-
lian cells (Elnakat & Ratnam 2004). Hence, blocking or
disrupting FRA will not a priori deprive a cell of neces-
sary folate and kill it. However, FRA has been reported
to impart a growth advantage to cells expressing the re-
ceptor, especially in low folate environments (Luhrs
et al. 1992). Furthermore, FRA’s high expression on epi-
thelial malignancies, compared to normal tissues, pro-
vides the rationale for its use as a potential targeted
cancer therapy. FRA targeted therapies are currently in
clinical investigation in both ovarian and lung cancers
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of such an approach in FRA expressing breast cancer. It
is worth repeating that FRA is expressed in normal
breast, restricted to the luminal borders of secretory
cells, consistent with the secretion of FRA into breast
milk. No other breast cell type has been shown to ex-
press FRA. Such an expression pattern in normal breast
tissue was seen in the present study although it should
be noted that not all samples, especially TMA cores,
contain normal tissue. The expression of FRA in carcin-
omas may reflect the cellular origin of the carcinoma
and may, at least in part, explain the approximately 30%
incidence in IDC demonstrated here.
Hormone receptor positive tumors appear to have a
lower incidence of FRA expression. FRA expression has
been shown to be regulated by steroid hormones, par-
ticularly estrogens (Rochman et al. 1985; Kelley et al.
2003). Specifically, 17β-estradiol has been demonstrated
to down-regulate FRA expression by direct action of the
estrogen receptor on the P4 promoter of FRA suggesting
a negative correlation between the expression of ER and
FRA. The data presented herein is in line with these
findings in that there was a clear association between
FRA(+) and ER(−) samples, i.e. ER(−) samples were sig-
nificantly more likely to be FRA(+).
A recent report (Hartmann et al. 2007) on a cohort of
63 invasive breast cancers, roughly equally distributed be-
tween good and poor outcome, demonstrated that strong
FRA staining was highly associated with poor outcome.
While the authors did not report on Her2 status of these
patients, it is interesting to speculate that the poor out-
come group may have included a significant TNBC popu-
lation. Studies are underway to assess the prognostic
significance of FRA expression in breast cancer and any
relationship to molecular subtype and histotype.
Our data, although limited by a small sample size,
demonstrate that approximately 30% of breast cancers
express FRA and suggest that as many as 70–80% of
stage IV metastatic TNBC tumors express this receptor.
FRA expressing breast cancer may, therefore, represent
an important and clinically significant subset of breast
cancer and in particular triple negative disease. FRA tar-
geted therapies, alone or in combination with cytotoxics,
may represent a novel approach to treatment for this
disease with a high unmet medical need.
Further work is clearly needed to confirm and extend
the present findings and to provide a clinical correlation
with FRA expression. Additional correlations with dis-
ease progression and response to treatment would be
interesting and potentially valuable in disease monitor-
ing and response assessments.
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